We have located links that may give you full text access.
Comparative Study
Journal Article
Macrocytic anemia during low-dose cisplatin and 5-Fluorouracil through implanted infusion port for unresectable hepatobilliary malignancies.
Anticancer Research 2005 March
UNLABELLED: The efficacy of continuous arterial infusion chemotherapy through a subcutaneously implanted port has been reported with less adverse effects than systemic chemotherapy in hepatobilliary malignancies. However, macrocytic anemia is sometimes seen during this therapy. In 25 patients (22 with hepatocellular carcinoma, 3 with cholangiocellular carcinoma) treated with cisplatinum (10mg/day) and 5-Fluorouracil (5-FU) (250 mg/day), the frequency of anemia and its etiologies were evaluated. Moreover, the two groups ("anemia" and "no anemia" group) were compared with their backgrounds. Nine cases (36%) showed macrocytic anemia without any evident etiologies during therapy. The cumulative appearance rate of anemia was 19% at 12 weeks and 51% at 18 weeks. The Child-Pugh score or Japanese integrated staging (JIS) score were significantly higher in the "anemia" group than that in the "no anemia" group.
CONCLUSION: Attention should be paid to slow progressive macrocytic anemia during low-dose cisplatinum and 5-FU, especially in patients with advanced liver cirrhosis.
CONCLUSION: Attention should be paid to slow progressive macrocytic anemia during low-dose cisplatinum and 5-FU, especially in patients with advanced liver cirrhosis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app